San Diego, CA, United States

Trilink Biotechnologies, Inc.

www.trilinkbiotech.com
San Diego, CA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | November 22, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Aptamers market is expected to grow from $109.23 million in 2015 to reach $346.14 million by 2022 with a CAGR of 17.9%. Huge R&D investments in bio-tech companies to develop applications in the field of diagnostics is the major factor propelling the market growth. In addition, high cost efficiency of aptamers, and technological developments are the key factors driving the market growth. However, strict regulations, ethical issues related to using aptamers, and lack of trained professional are the factors inhibiting the market growth.  Access the complete report at: http://www.strategymrc.com/report/aptamers-market Nucleic acid aptamers segment is witnessing a significant growth driven by increasing research and development activities and growing usage in diagnostic applications for the treatment of diseases such as autoimmune diseases, cancer and HIV/AIDS.  North America is anticipated to be the largest market for aptamers, whereas Asia Pacific is projected to grow at a faster pace. Favorable government initiatives and increased research and development activities in the U.S are propelling the market growth in North America region. Some of the key players in global aptamers market include Bioapter S.L., Base Pair Biotechnologies, Inc., Optech Biotech, Ophthotech Corporation, NOXXON Pharma AG, Neoventures Biotechnology Inc., CD Genomics, Aptagen, LLC, Am Biotechnologies, LLC, Aptus Biotech S.L., Aptamer Solutions Ltd., Aptamer Sciences Inc., Vivonics, Inc., Trilink Biotechnologies, Inc., Somalogic, Inc., and Regado Biosciences, Inc. Request for a sample at: http://www.strategymrc.com/report/aptamers-market Aptamer Types Covered: • Nucleic Acid Aptamers o DNA-Based o RNA-Based • Peptide Aptamers Applications Covered: • Diagnostics o Biomarker Detection and Discovery o Molecular Imaging • Therapeutics Development • Research and Development o Drug Discovery and Development o Targeted Drug Delivery • Other Applications o Biosensor o Food Safety Technologies Covered: • SELEX • Other Technologies End Users Covered: • Bio-Tech Companies • Academia • CRO's • Other End Users Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain      o Rest of Europe  • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements


News Article | November 3, 2016
Site: marketersmedia.com

— Huge R&D investments in bio-tech companies to develop applications in the field of diagnostics is the major factor propelling the market growth. In addition, high cost efficiency of aptamers, and technological developments are the key factors driving the market growth. However, strict regulations, ethical issues related to using aptamers, and lack of trained professional are the factors inhibiting the market growth. Nucleic acid aptamers segment is witnessing a significant growth driven by increasing research and development activities and growing usage in diagnostic applications for the treatment of diseases such as autoimmune diseases, cancer and HIV/AIDS. North America is anticipated to be the largest market for aptamers, whereas Asia Pacific is projected to grow at a faster pace. Favorable government initiatives and increased research and development activities in the U.S are propelling the market growth in North America region. Some of the key players in global aptamers market include Bioapter S.L., Base Pair Biotechnologies, Inc., Optech Biotech, Ophthotech Corporation, NOXXON Pharma AG, Neoventures Biotechnology Inc., CD Genomics, Aptagen, LLC, Am Biotechnologies, LLC, Aptus Biotech S.L., Aptamer Solutions Ltd., Aptamer Sciences Inc., Vivonics, Inc., Trilink Biotechnologies, Inc., Somalogic, Inc., and Regado Biosciences, Inc. Applications Covered: • Diagnostics o Biomarker Detection and Discovery o Molecular Imaging • Therapeutics Development • Research and Development o Drug Discovery and Development o Targeted Drug Delivery • Other Applications o Biosensor o Food Safety Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com/


Snead N.M.,Beckman Research Institute | Escamilla-Powers J.R.,Trilink Biotechnologies, Inc. | Rossi J.J.,Beckman Research Institute | McCaffrey A.P.,Trilink Biotechnologies, Inc.
Molecular Therapy - Nucleic Acids | Year: 2013

Optimization of small interfering RNAs (siRNAs) is important in RNA interference (RNAi)-based therapeutic development. Some specific chemical modifications can control which siRNA strand is selected by the RNA-induced silencing complex (RISC) for gene silencing. Intended strand selection will increase potency and reduce off-target effects from the unintended strand. Sometimes, blocking RISC loading of the unintended strand leads to improved intended strand-silencing potency, but the generality of this phenomenon is unclear. Specifically, unlocked nucleic acid (UNA) modification of the 5′ end of canonical (i.e., 19+2) siRNAs abrogates gene silencing of the modified strand, but the fate and potency of the unmodified strand has not been investigated. Here, we show that 5′ UNA-modified siRNAs show improved silencing potency of the unmodified strand. We harness this advantageous property in a therapeutic context, where a limited target region in a conserved HIV 5′ long terminal repeat U5 region would otherwise yield siRNAs with undesired strand selection properties and poor silencing. Applying 5′ UNA modification to the unintended sense (S) strand of these otherwise poorly targeted siRNAs dramatically improves on-target silencing by the intended antisense (AS) strand in pNL4-3.luciferase studies. This study highlights the utility of 5′ UNA siRNA modification in therapeutic contexts where siRNA sequence selection is constrained. © 2013 The American Society of Gene & Cell Therapy All rights reserved.


Paul N.,Trilink Biotechnologies, Inc.
Methods in molecular biology (Clifton, N.J.) | Year: 2010

Hot Start activation approaches are increasingly being used to improve the performance of PCR. Since the inception of Hot Start as a means of blocking DNA polymerase extension at lower temperatures, a number of approaches have been developed that target the essential reaction components such as magnesium ion, DNA polymerase, oligonucleotide primers, and dNTPs. Herein, five different Hot Start activation protocols are presented. The first method presents the use of barriers as a means of segregating key reaction components until a Hot Start activation step. The second and third protocols demonstrate Hot Start approaches to block DNA polymerase activity through the use of anti-DNA polymerase antibodies and accessory proteins, respectively. The fourth and fifth protocols utilize thermolabile chemical modifications to the oligonucleotide primers and dNTPs. The results presented demonstrate that all protocols significantly improve the specificity of traditional thermal cycling protocols.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 99.46K | Year: 2011

DESCRIPTION (provided by applicant):The Ligase Chain Reaction (LCR) is a DNA amplification technique that can either be utilized in conjunction with Polymerase Chain reaction (PCR), or as an alternative to PCR, due to its equal ability to support exponential signal amplification. LCR is being used as a tool in molecular biology and diagnostic applications, especially for nucleotide sequence detection and single nucleotide polymorphism (SNP) detection. However, performance problems and non-specificity issues, including the accumulation of false-positive signals, often make conventional LCR an unlikely choice in clinical diagnostics and in the development of ligation-based applications. Herein, we propose a novel Hot Start approach for LCR. Similar to the benefit seen for Hot Start activation methods in PCR, the Hot Start LCR approach is predicted to have substantially improved specificity and performance, compared to conventional LCR. Hot Start LCR employs chemically modified ligation components, including oligonucleotide probes and cofactors, containing thermally labile protecting groups for heat-triggered LCR. We believe that this approach will be a significant improvement to current methods because it has the high potential to replace a number of applications where traditional PCR, Gap-LCR or PCR/ligation combination approaches are either expensive, not applicable, or show problematic performance. PUBLIC HEALTH RELEVANCE: As of 2009, the molecular diagnostics market has an average annual growth rate of12- 15%, with an estimated value of 3-3.5 billion worldwide, where 2 to 2.5 billion of the market is in the USA. The Ligase Chain Reaction (LCR) is a substantial component of this market. We propose to improve the specificity of conventional LCR by developing a novel approach that includes Hot Start activation of LCR by using modified oligonucleotide probes and cofactors with thermolabile protecting groups.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 132.80K | Year: 2013

DESCRIPTION (provided by applicant): Next generation sequencing (NGS) technologies are a rapidly developing area, with the ability to produce gigabases of sequencing data at reduced costs. While NGS is best recognized for genomic DNA sequencing (DNA-Seq),there is a significant body of work to expand the breadth of sample types being studied. RNA deep sequencing (RNA-Seq) is a well-developed segment of NGS experimentation, with a growing focus on small RNA deep sequencing (smRNA-Seq). One of the limitationsin the deep sequencing of the 20-30 nt small RNA is in the sample preparation workflow, which requires several purification steps. As with all RNA samples, NGS sample preparation involves the ligation of fixed sequences, called adapters, onto the 5 and 3ends of the starting RNA library. This ligation step can be plagued by the undesired joining of the adapter sequences to one another without a segment of the library in between, resulting in adapter dimer formation. Although affinity capture can be usedto remove adapter dimers in most library prep workflows, adapter-tagged small RNA libraries are too close in size to the adapter dimers for effective use of this approach. As result, a gel purification step is required, which can deplete low abundance sequences. To avoid making unintentional changes to the complexity of the library, it is advantageous to block adapter dimer formation at the ligation step. With this goal in mind, we propose a novel approach to RNA sample preparation for NGS that uses TriLink's expertise in nucleic acid chemistry to disfavor adapter-adapter ligation while allowing for efficient joining of adapter probes on the 5'and 3' ends of the library. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Next generation sequencing(NGS) is maturing into an essential technique for RNA and DNA sequence analysis. NGS is a major component of the genomics market which was valued at 5.8 billion in 2009. We propose the investigation of chemically-modified components to streamline NGS experimental workflows for small RNA deep sequencing.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 727.80K | Year: 2010

DESCRIPTION (provided by applicant): DNA ligases are more frequently being used as a tool in molecular biology applications that include nucleotide sequence detection, single nucleotide polymorphism (SNP) detection, protein detection, and next generation sequencing by ligation. With the increased demand for DNA ligases in the field of biotechnology, so is the need for improved fidelity of ligation. Although many approaches to improving ligation fidelity have been employed, most involve use of ligases from different biological sources, point mutations of key amino acid residues, and modified reaction conditions. Herein, we propose a slightly different approach to improving the stringency of ligation, which employs a set of chemically modified ligation components. In our three-pronged approach, we propose the evaluation of chemically modified variants of the ATP cofactor, the donor probe, and the acceptor probe. The significance of this approach is great because each of these three components makes contacts with different key amino acid contacts within the ligase. It is hoped that subtle chemical alterations to the nucleic acid component of DNA ligase may in turn induce an improvement in the fidelity of ligation. PUBLIC HEALTH RELEVANCE: The field of molecular diagnostics is a growing market with a current estimated value of 20.5 billion. One key class of enzymes that are used in these efforts is the DNA dependent DNA ligases. To further improve the accuracy of the DNA joining reaction catalyzed by DNA ligases, we propose the investigation of chemically modified components.


Trademark
Trilink Biotechnologies, Inc. | Date: 2016-08-04

Fine chemicals for contract synthesis/research, namely, modified oligonucleotides; nucleosides and nucleotides. Computerized online ordering services in the field of custom and contract synthesis, and manufacture of standard and modified oligonucleotides, nucleosides, and nucleotides. Providing custom synthesis, manufacture and combination to specification of fine chemicals which are standard and custom modified oligonucleotides, nucleosides and nucleotides, available online.


Patent
Trilink Biotechnologies, Inc. | Date: 2013-03-15

Provided herein are methods for ligation of polynucleotides containing modified ligation components, particularly modified ligase cofactors, modified acceptors and modified donors. The methods readily applied to ligation-based assays for detection of a nucleic acid sequence where the use of the modified cofactor improves discrimination between matched and mismatched templates. Furthermore, the use of the modified ligation components reduces or eliminates the ligation in the absence of nucleic acid template. In addition, methods are applied to the preparation of nucleic acid libraries using modified acceptor probes and modified donor probes that reduce or eliminate probe dimerization during the ligation process.


Patent
Trilink Biotechnologies, Inc. | Date: 2013-07-03

Provided herein are methods for ligase mediated nucleic acid replication and amplification of oligo- and probes containing substituted ligase components, particularly substituted ligase cofactors, substituted oligo- and probe acceptors, substituted oligo- and probe donors, substituted adenylated oligo- and polynucleotide donor intermediates carrying thermolabile group or groups. The substituted ligase components are not active until Hot Start activation step converts them into unsubstituted or natural ligase components, which fully support ligase reaction. The described methods are readily applied to ligation-based assays, especially utilizing Ligase Chain Reaction (LCR), for detection of a nucleic acid sequence where the use of the substituted ligase components improves an overall efficiency of LCR, increase discrimination between matched and mismatched templates and reduces or eliminates appearance of false positive signal. Furthermore, the use of the substituted ligase components reduces or eliminates the false positive signal originated from the template independent and blunt-ended ligation.

Loading Trilink Biotechnologies, Inc. collaborators
Loading Trilink Biotechnologies, Inc. collaborators